Search

Displaying results 931 - 940 of 4238 in total
  1. Drug

    Mivacurium

    go.drugbank.com/drugs/DB01226
    ApprovedWithdrawn

    Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscul...

  2. Drug

    Metipranolol

    go.drugbank.com/drugs/DB01214
    ApprovedWithdrawn

    It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

  3. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    It is available in topical formulations for the treatment of skin infections such as athlete's foot.

  4. Drug

    Estriol

    go.drugbank.com/drugs/DB04573
    ApprovedInvestigationalVet approved

    Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada.

  5. Drug

    Memantine

    go.drugbank.com/drugs/DB01043
    ApprovedInvestigational

    It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease

  6. Drug

    Valproic acid

    go.drugbank.com/drugs/DB00313
    ApprovedInvestigational

    [A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century.

  7. Drug

    Tremelimumab

    go.drugbank.com/drugs/DB11771
    ApprovedInvestigational

    CTLA-4 is a cell surface receptor expressed on activated T cells to act as a negative regulator for T cells. … Tremelimumab, formerly known as ticilimumab, is a fully human IgG2 monoclonal antibody directed against cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).

  8. Drug

    Teclistamab

    go.drugbank.com/drugs/DB16655
    ApprovedInvestigational

    [A253587] On August 24, 2022, the European Commission (EC) granted conditional marketing authorization of teclistamab as first-in-class bispecific antibody for the treatment of multiple myeloma, marking

  9. Drug

    Lorlatinib

    go.drugbank.com/drugs/DB12130
    ApprovedInvestigational

    approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as … Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018

  10. Drug

    Verteporfin

    go.drugbank.com/drugs/DB00460
    ApprovedInvestigational

    It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. … Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative comprising a 50:50 mixture of two isomers: [CL-315555] and [CL-315585].